ACTSI Investigator Dr. Sagar Lonial in the News

Sagar Lonial, MD, ACTSI investigator, professor and vice chairman of clinical affairs at Emory University School of Medicine department of hematology and medical oncology, and director of translational research for the B-cell malignancy program at Winship Cancer Institute

ASCO Post | Unraveling the molecular complexity of multiple myeloma
April 15, 2014

Lab Land | Cellular response to stress: autophagy
November 13, 2013

Lonial received a top award from the Multiple Myeloma Research Foundation (MMRF), the MMRF Accelerator Award. He was recognized for his outstanding efforts and exceptional contributions to starting new clinical trials through the Multiple Myeloma Research Consortium and rapidly enrolling patients in those trials.

Lonial was also a recipient of the 2013  Emory Millipub Award. The distinction is given to faculty with papers cited one thousand times or more.

He received the Celgene 2012 Young Investigator Award for Clinical Research in Hematology. 

Winship opened a new trial of a CD38 antibody called daratumumab. Lonial is principal investigator of the study at Winship. According to Lonial, daratumumab is one of the most exciting new agents in multiple myeloma, and there are very few sites that have the drug available. Lonial and his team have started screening patients and delivered the first dose overall on the study. The trial opened very rapidly (close to 45 days) and the first two patients have already started treatment. This agent falls into the new FDA category of breakthrough designation, and thus, it will likely be the registration study for accelerated approval.

LA Canada | Successful blood cancer therapy identified
May 30, 2012

Genetic Engineering & Biotechnology News | Partnership seeks multiple myeloma biomarkers and drugs
September 24, 2012 | Next-generation proteasome inhibitor approved in multiple myeloma
November 8, 2012

Emory Health Sciences | When Bone Marrow Goes Bad
Winter 2011

In the News 2011-2012